Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLN-74809 Receptor Occupancy PET Study in IPF
NCT04072315Phase 2Completed
- Sponsor
- Pliant Therapeutics
- Start
- Feb 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bexotegrast in idiopathic pulmonary fibrosis (IPF) (5 arms), sponsored by Pliant Therapeutics. Primary endpoint: Number of Participants With a Predicted Effect on αVβ6 PET in Lungs After Administration of Drug at 1 day. Started Feb 2020; status: completed.
02
Drugs
bexotegrast
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04072315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04072315.